Brookline Capital Management Begins Coverage on iBio (NYSE:IBIO)

Brookline Capital Management started coverage on shares of iBio (NYSE:IBIO) in a research note issued to investors on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $3.60 price objective on the stock.

A number of other research analysts have also recently issued reports on the stock. StockNews.com began coverage on shares of iBio in a report on Saturday, April 20th. They issued a sell rating for the company. Chardan Capital reiterated a buy rating and issued a $5.00 price target on shares of iBio in a research report on Monday, June 3rd.

iBio Price Performance

NYSE IBIO opened at $2.16 on Monday. iBio has a 52-week low of $1.02 and a 52-week high of $15.99. The business’s 50-day moving average price is $2.22. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.69 and a quick ratio of 1.69.

iBio (NYSE:IBIO) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.71) earnings per share (EPS) for the quarter. On average, analysts predict that iBio will post -99.82 EPS for the current year.

Hedge Funds Weigh In On iBio

A number of large investors have recently bought and sold shares of the stock. Ikarian Capital LLC purchased a new position in shares of iBio in the 1st quarter valued at $2,436,000. Opaleye Management Inc. purchased a new stake in iBio during the 1st quarter worth $2,761,000. Finally, Lynx1 Capital Management LP purchased a new stake in iBio during the 1st quarter worth $2,436,000. Hedge funds and other institutional investors own 7.90% of the company’s stock.

About iBio

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.